Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: A randomized double-blinded placebo-controlled study

International Journal of Cardiology

Volumn 161, Issue 3, 2012, Pages 137-142

  Doehner, Wolfram ^a   Todorovic, Johanna ^a   Kennecke, Cornelia ^a   Rauchhaus, Mathias ^a   Sandek, Anja ^a   Lainscak, Mitja ^b   Van Linthout, Sophie ^a   Tschöpe, Carsten ^a   Von Haehling, Stephan ^a   Anker, Stefan D ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b University Clinic of Respiratory Diseases   (Slovenia)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Angiotensin receptor antagonist; Chronic heart failure; Endothelium function; Insulin sensitivity; PPAR gamma

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; N(G),N(G) DIMETHYLARGININE; PLACEBO; RESISTIN; SPIRONOLACTONE;

ADULT; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; PARALLEL DESIGN; PATIENT COMPLIANCE; PLETHYSMOGRAPHY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; BIPHENYL COMPOUNDS; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; VASODILATION;

EID: 84869507142     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.07.051     Document Type: Article

References (37)

1. A.J. Coats The muscle hypothesis of chronic heart failure J Mol Cell Cardiol 28 1996 2255 2262
2. J.W. Swan, S.D. Anker, C. Walton, I.F. Godsland, A.L. Clark, and F. Leyva Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure J Am Coll Cardiol 30 1997 527 532
3. J.G. Cleland, K. Swedberg, F. Follath, M. Komajda, A. Cohen-Solal, and J.C. Aguilar Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis Eur Heart J 24 2003 442 463
4. N. Suskin, R.S. McKelvie, R.J. Burns, R. Latini, D. Pericak, and J. Probstfield Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure Eur Heart J 21 2000 1368 1375
5. W. Doehner, M. Rauchhaus, P. Ponikowski, I.F. Godsland, S. von Haehling, and D.O. Okonko Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure J Am Coll Cardiol 46 2005 1019 1026
6. T.D. Giles, A.B. Miller, U. Elkayam, M. Bhattacharya, and A. Perez Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction J Card Fail 14 2008 445 452
7. R. Fogari, A. Zoppi, I. Ferrari, A. Mugellini, P. Preti, and P. Lazzari Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients Horm Metab Res 41 2009 893 898
8. G. Derosa, E. Fogari, A. D'Angelo, A.F. Cicero, S.A. Salvadeo, and P.D. Ragonesi Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone J Clin Pharm Ther 32 2007 261 268
9. M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity Circulation 109 2004 2054 2057
10. NAVIGATOR Study Group Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
11. J.W. Swan, C. Walton, and I.F. Godsland Assessment of insulin sensitivity in man: a comparison of minimal model and euglycaemic clamp derived measures in health and heart failure Clin Sci 86 1994 317 322
12. R.N. Bergman, Y.Z. Ider, C.R. Bowden, and C. Cobelli Quantitative estimation of insulin sensitivity Am J Physiol 236 1979 E667 E677
13. T. Szabo, S. von Haehling, D. Habedank, M. Rauchhaus, M. Lainscak, and A. Sandek Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure Int J Cardiol 147 2011 47 51
14. W. Doehner, and S.D. Anker Godsland IF Optimising insulin sensitivity assessment using the modelling method in chronic heart failure Horm Metab Res 37 2005 106 110
15. S.D. Anker, P.P. Ponikowski, A.L. Clark, F. Leyva, M. Rauchhaus, and M. Kemp Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure Eur Heart J 20 1999 683 693
16. W. Doehner, M. Rauchhaus, V.G. Florea, R. Sharma, A.P. Bolger, and C.H. Davos Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance Am Heart J 141 2001 792 799
17. S. von Haehling, E.A. Jankowska, N.G. Morgenthaler, C. Vassanelli, L. Zanolla, and P. Rozentryt Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure J Am Coll Cardiol 50 2007 1973 1980
18. J. Frystyk, L. Tarnow, T.K. Hansen, H.H. Parving, and A. Flyvbjerg Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications Diabetologia 48 2005 1911 1918
19. J. Martens-Lobenhoffer, and S.M. Bode-Böger Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry Clin Chem 52 2006 488 493
20. W. Doehner, M. Rauchhaus, I.F. Godsland, K. Egerer, J. Niebauer, and R. Sharma Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha Int J Cardiol 83 2002 73 81
21. A.J. Murray, R.E. Anderson, G.C. Watson, G.K. Radda, and K. Clarke Uncoupling proteins in human heart Lancet 364 2004 1786 1888
22. R.M. Witteles, and M.B. Fowler Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options J Am Coll Cardiol 51 2008 93 102
23. H. Tuunanen, E. Engblom, A. Naum, K. Någren, M. Scheinin, B. Hesse, Airaksinen K.E. Juhani, P. Nuutila, P. Iozzo, H. Ukkonen, L.H. Opie, and J. Knuuti Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy Circulation 118 2008 1250 1258
24. 13C nuclear magnetic resonance spectroscopy N Engl J Med 322 1990 262 263
25. A.L. Clark, P.A. Poole-Wilson, and A.J. Coats Exercise limitation in chronic heart failure: central role of the periphery J Am Coll Cardiol 28 1996 1092 1102
26. W. Doehner, C.D. Pflaum, M. Rauchhaus, I.F. Godsland, K. Egerer, and M. Cicoira Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia Eur J Endocrinol 145 2001 727 735
27. S. Yusuf, J.B. Ostergren, H.C. Gerstein, M.A. Pfeffer, K. Swedberg, and C.B. Granger Candesartan in heart failure - assessment of reduction in mortality and morbidity program investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure Circulation 112 2005 48 53
28. S.E. Kjeldsen, S. Julius, G. Mancia, G.T. McInnes, T. Hua, and M.A. Weber VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial J Hypertens 24 2006 1405 1412
29. W.J. Elliott, and P.M. Meyer Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 369 9557 2007 Jan 20 201 207
30. M. Schupp, M. Clemenz, R. Gineste, H. Witt, J. Janke, and S. Helleboid Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity Diabetes 54 2005 3442 3452
31. R. Fogari, A. Zoppi, P. Preti, E. Fogari, G. Malamani, and A. Mugellini Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women Am J Hypertens 14 2001 921 926
32. The ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
33. B.M. Massie, P.E. Carson, J.J. McMurray, M. Komajda, R. McKelvie, and M.R. Zile I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med 359 2008 2456 2467
34. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
35. S. Lund, G.D. Holman, O. Schmitz, and O. Pedersen Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin Proc Natl Acad Sci U S A 92 1995 5817 5821
36. W. Doehner, D. Gathercole, M. Cicoira, A. Krack, A.J. Coats, and P.G. Camici Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition Int J Cardiol 138 2010 19 24
37. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2